Tumor-infiltrating Lymphocytes As a Predictive Biomarker of Cutaneous Immune-related Adverse Events After Immune Checkpoint Blockade in Patients with Advanced Melanoma

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 2023 Feb 22

PMID 36806644

Authors

Michael R Stephens

Maria S Asdourian

Ted V Jacoby

Nishi Shah

Leah L Thompson

Tracey Otto

Yevgeniy R Semenov

Kerry L Reynolds

Ryan J Sullivan

Ruth K Foreman

Steven T Chen

Affiliations

Soon will be listed here.

Citing Articles

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

van Duin I, Schuiveling M, Ter Maat L, Veta M, van Eijs M, Verheijden R Immunooncol Technol. 2024; 24:100714.

PMID: 39045171 PMC: 11262179. DOI: 10.1016/j.iotech.2024.100714.

Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.

Vargas G, Shafique N, Xu X, Karakousis G Expert Rev Mol Diagn. 2024; 24(4):299-310.

PMID: 38314660 PMC: 11134288. DOI: 10.1080/14737159.2024.2312102.

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.

Cao T, Zhou X, Wu X, Zou Y Front Immunol. 2023; 14:1207544.

PMID: 37497220 PMC: 10368482. DOI: 10.3389/fimmu.2023.1207544.

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.

Chatziioannou E, Rossner J, Aung T, Rimm D, Niessner H, Keim U EBioMedicine. 2023; 93:104644.

PMID: 37295047 PMC: 10363450. DOI: 10.1016/j.ebiom.2023.104644.

References

Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G . The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018; 35(3):25. DOI: 10.1007/s12032-018-1080-0. View

Maibach F, Sadozai H, Seyed Jafari S, Hunger R, Schenk M . Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Front Immunol. 2020; 11:2105. PMC: 7511547. DOI: 10.3389/fimmu.2020.02105. View

Yang J, Lian J, Chin Y, Wang L, Lian A, Murphy G . Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Melanoma Using Pathologic Features Identified by Natural Language Processing. JAMA Netw Open. 2021; 4(9):e2126337. PMC: 8459191. DOI: 10.1001/jamanetworkopen.2021.26337. View

Nakamura Y . Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front Med (Lausanne). 2019; 6:119. PMC: 6549005. DOI: 10.3389/fmed.2019.00119. View